TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8402734

Group type: EXPERIMENTAL
Intervention: 0.18 MIU/m2 IL-2 s.c. once weekly
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 0.9 MIU/m2 IL-2 s.c. thrice weekly every other day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 4.5 MIU/m2 IL-2 s.c. five times weekly every other week
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: IL-2 treatment
Number of subjects: 46
Study: 3710959

Group type: EXPERIMENTAL
Intervention: 1 g aztreonam iv twice daily for 4 to 15 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: 1 g cefotaxime iv twice daily for 4 to 15 days
Number of subjects: 39
Study: 29413437

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Treatment for NAS
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (not treated for NAS)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Maternal parenting stress
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Maternal home environment
Number of subjects: 96
Study: 26526080

Group type: EXPERIMENTAL
Intervention: Fecal Occult Blood Testing (FOBT)
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Choice between FOBT and Colonoscopy
Number of subjects: 997

Group type: COMPARATOR
Intervention: Patient Navigation
Number of subjects: 997
Study: 24978441

Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol Easyhaler (EH)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Symbicort Turbuhaler (TH)
Number of subjects: 187
Study: 22116105

Group type: EXPERIMENTAL
Intervention: MR perfusion imaging
Number of subjects: 59
Study: 20537811

Group type: EXPERIMENTAL
Intervention: Seeking Safety intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health education intervention
Number of subjects: 0
Study: 18767580

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with rehabilitation therapy (group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Scalp acupuncture (group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rehabilitation therapy (group B)
Number of subjects: 90
Study: 16507374

Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D (calcium carbonate 500 mg and vitamin D3 400 IU taken twice daily)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D
Number of subjects: 192
Study: 12358234

Group type: EXPERIMENTAL
Intervention: Lansoprazole (15 mg or 30 mg once daily)
Number of subjects: 692

Group type: COMPARATOR
Intervention: Ranitidine (150 mg b.i.d.)
Number of subjects: 692
Study: 10593375

Group type: EXPERIMENTAL
Intervention: VEGF levels in follicular fluid
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Leptin levels in follicular fluid
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: NO levels in follicular fluid
Number of subjects: 16
Study: 8915237

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME) (Hygrobac‐DAR)
Number of subjects: 15
Study: 1860433

Group type: EXPERIMENTAL
Intervention: Endotracheal suction 6-hourly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endotracheal suction 12-hourly
Number of subjects: 0
Study: 6434794

Group type: EXPERIMENTAL
Intervention: Glibenclamide 10 mg/d for 6 weeks
Number of subjects: 40
Study: 30249082

Group type: EXPERIMENTAL
Intervention: Antiperspirant product containing agaricine, aluminum hydrochloride, and silver citrate, applied once in a laboratory setting and then used at home for 14 days.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Antiperspirant product after repeated home applications for 14 days.
Number of subjects: 20
Study: 29907752

Group type: EXPERIMENTAL
Intervention: microcrystalline cellulose pellets (500 mg samples)
Number of subjects: 132
Study: 28028984

Group type: EXPERIMENTAL
Intervention: Whole-body cryostimulation (WBC) with subsequent kinesiotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Kinesiotherapy (KT)
Number of subjects: 32
Study: 25493120

Group type: EXPERIMENTAL
Intervention: DCLHb
Number of subjects: 219
Study: 21655909

Group type: EXPERIMENTAL
Intervention: Acid-etched titanium caps
Number of subjects: 10

Group type: COMPARATOR
Intervention: Machined titanium caps
Number of subjects: 10
Study: 20093909

Group type: EXPERIMENTAL
Intervention: Daily gentamicin (5 mg/kg IV, then 2 placebo doses IV after 8 and 16 hours)
Number of subjects: 126

Group type: COMPARATOR
Intervention: 8-hour gentamicin (2 mg/kg IV, then 1.5 mg/kg IV after 8 and 16 hours)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both groups received ampicillin (2 grams IV every 6 hours for a total of four doses) and patients who underwent cesarean delivery also received clindamycin (900 mg IV every 8 hours, for a total of three doses).
Number of subjects: 126
Study: 17268894

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16351337

Group type: EXPERIMENTAL
Intervention: Welfare and antipoverty policies during the transition into middle childhood
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Welfare and antipoverty policies during the transition out of middle childhood into early adolescence
Number of subjects: 30000
Study: 11862965

Group type: EXPERIMENTAL
Intervention: ECP monitoring group
Number of subjects: 164

Group type: COMPARATOR
Intervention: PEF monitoring group
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: ECP and PEF monitoring groups
Number of subjects: 164
Study: 10207779

Group type: EXPERIMENTAL
Intervention: OAC 20 regimen (Omeprazole 20 mg daily, Amoxycillin 500 mg t.d.s., Clarithromycin 200 mg b.d.)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: LAC 30 regimen (Lansoprazole 30 mg daily, Amoxycillin 500 mg t.d.s., Clarithromycin 200 mg b.d.)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: OAC 40 regimen (Omeprazole 20 b.d., Amoxycillin 500 mg t.d.s., Clarithromycin 200 mg b.d.)
Number of subjects: 224
Study: 7617349

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Regional anesthesia
Number of subjects: 80
Study: 2171275

Group type: EXPERIMENTAL
Intervention: Benzonal
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Finlepsin
Number of subjects: 40
Study: 334315

Group type: EXPERIMENTAL
Intervention: High dosage haloperidol (100 mg daily) for three months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (chlorpromazine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dosage haloperidol (100 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up period after haloperidol
Number of subjects: 0
Study: 30754068

Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 64

Group type: COMPARATOR
Intervention: Fixed-bearing TKA
Number of subjects: 64
Study: 31385001

Group type: COMPARATOR
Intervention: Quizartinib 30 mg alone (reference)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg once daily (days 1-5) + single-dose quizartinib 30 mg (day 5) (test)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Quizartinib alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lansoprazole + quizartinib
Number of subjects: 64
Study: 26873392

Group type: EXPERIMENTAL
Intervention: Anise oil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Colpermin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 26337978

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 μg/vilanterol 25 μg once-daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing therapy (control group)
Number of subjects: 0
Study: 23578227

Group type: EXPERIMENTAL
Intervention: N7‐GP 25 μg kg(‐1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: N7‐GP 100 μg kg(‐1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: N7‐GP 200 μg kg(‐1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: N7‐GP (all doses)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Observation period with on-demand treatment of rFVIIa
Number of subjects: 23
Study: 21119069

Group type: EXPERIMENTAL
Intervention: Icodextrin
Number of subjects: 0
Study: 19188550

Group type: EXPERIMENTAL
Intervention: Bosentan (62.5 mg on day 1, 125 mg on days 2 and 3)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 17307892

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (1500 impulses at 14 KV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conservative treatment (nonsteroidal anti-inflammatory drugs, physiotherapy, exercise program, knee strap)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 50
Study: 14996107

Group type: EXPERIMENTAL
Intervention: 0.1% melatonin applied once daily for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo solution applied once daily for 6 months
Number of subjects: 40
Study: 11697758

Group type: EXPERIMENTAL
Intervention: Dofetilide (0.5 mg bid)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dofetilide (0.5 mg bid) + Verapamil (80 mg tid)
Number of subjects: 12
Study: 9458447

Group type: EXPERIMENTAL
Intervention: Inogatran (low dose)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Inogatran (medium dose)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Inogatran (high dose)
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1209
Study: 8198309

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 98

Group type: COMPARATOR
Intervention: 0.5% diphenhydramine
Number of subjects: 98
Study: 3370405

Group type: EXPERIMENTAL
Intervention: Salad with toppings (600 g) with small beverage
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbonated beverage (800 ml)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bean burritos and one bean tostada (900 g) with small beverage
Number of subjects: 10
Study: 29666118

Group type: EXPERIMENTAL
Intervention: Initial R-chemotherapy ± R maintenance
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: PRIMA-prognostic index (PRIMA-PI)
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Validation cohort (FL2000 LYSA trial and University of Iowa/Mayo Clinic)
Number of subjects: 1135
Study: 28689041

Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 65
Study: 26254752

Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride (ultrashort‐acting β‐blocker)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no landiolol)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride
Number of subjects: 60
Study: 23823157

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin with twice-daily radiation
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus cisplatin with twice-daily radiation
Number of subjects: 93
Study: 20701479

Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 45

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 45
Study: 18552270

Group type: EXPERIMENTAL
Intervention: Erythropoietin stimulating agents (ESAs)
Number of subjects: 0
Study: 16616165

Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patch (NP)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 42 mg nicotine patch (NP)
Number of subjects: 130
Study: 15030300

Group type: EXPERIMENTAL
Intervention: Therapies targeted against reactive oxygen intermediates (not specified dosage or duration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antioxidants (not specified dosage or duration)
Number of subjects: 0
Study: 10985710

Group type: EXPERIMENTAL
Intervention: Non-ST-segment elevation MI patients
Number of subjects: 881

Group type: COMPARATOR
Intervention: ST-segment elevation MI patients
Number of subjects: 881
Study: 8618139

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2000 or 3000 mg for 16 weeks)
Number of subjects: 22
Study: 1466444

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no bupivacaine)
Number of subjects: 30
Study: 6741150

Group type: EXPERIMENTAL
Intervention: 2 times 250 ml protein‐free dialysate of calf blood (Solcoseryl) in saline solution over 9 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28570494

Group type: EXPERIMENTAL
Intervention: HRV-guided training (HRVG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 36
Study: 29641184

Group type: COMPARATOR
Intervention: Messaging-only arm (n = 237)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Standard testing arm (n = 173)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Test kit arm (n = 179)
Number of subjects: 589
Study: 26560732

Group type: EXPERIMENTAL
Intervention: Surveillance CT colonography (CTC)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Preliminary colonoscopy (OC)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Surveillance CTC
Number of subjects: 82
Study: 24120672

Group type: EXPERIMENTAL
Intervention: Intradermal vaccine (15μg HA/strain)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Intradermal vaccine (21μg HA/strain)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: High-dose intramuscular vaccine (60μg HA/strain)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Standard-dose intramuscular vaccine (15μg HA/strain)
Number of subjects: 636
Study: 22674470

Group type: EXPERIMENTAL
Intervention: Oral solution of 10 μg deuterated Phenanthrene ([D₁₀]Phe)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Smoking cigarettes containing 10 μg deuterated Phenanthrene ([D₁₀]Phe)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: GSTM1-null subjects
Number of subjects: 25
Study: 19288563

Group type: EXPERIMENTAL
Intervention: CME with practice enablers and reinforcers (PER)
Number of subjects: 122

Group type: COMPARATOR
Intervention: CME only (control group)
Number of subjects: 122
Study: 17635247

Group type: EXPERIMENTAL
Intervention: PRP/BG
Number of subjects: 29

Group type: COMPARATOR
Intervention: BG
Number of subjects: 29
Study: 16175592

Group type: EXPERIMENTAL
Intervention: Exercise bronchial challenge test
Number of subjects: 545
Study: 12232564

Group type: EXPERIMENTAL
Intervention: Verapamil (0.15 mg/kg at a rate of 2 mg/min)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Ibutilide (1 mg over 10 minutes)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Verapamil and/or ibutilide
Number of subjects: 223

Group type: COMPARATOR
Intervention: Verapamil and ibutilide
Number of subjects: 223
Study: 10086657

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (400 mg twice daily) plus metronidazole (400 mg) and tetracycline (500 mg) four times daily for 1 week (RMT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Colloidal bismuth subcitrate (120 mg), metronidazole (400 mg), and tetracycline (500 mg) four times daily for 1 week (BMT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RMT
Number of subjects: 100

Group type: COMPARATOR
Intervention: BMT
Number of subjects: 100
Study: 7722691

Group type: EXPERIMENTAL
Intervention: CT1 (1 period of intervention, n = 113)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: CT2 (2 periods of intervention, n = 64)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: CT3 (3 periods of intervention, n = 62)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: CT4 (4 periods of intervention, n = 62)
Number of subjects: 301
Study: 2397315

Group type: EXPERIMENTAL
Intervention: Case vignette with diagnosis of alcohol dependence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Case vignette without diagnosis of alcohol dependence
Number of subjects: 0
Study: 7394499

Group type: EXPERIMENTAL
Intervention: 0.2 mg oxitropium bromide
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.2 mg oxitropium bromide at 7.30 a.m. after placebo
Number of subjects: 15
Study: 31090589

Group type: EXPERIMENTAL
Intervention: Treat-to-target (T2T) strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study: 27615515

Group type: EXPERIMENTAL
Intervention: Video-game exercise (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting list control (n=30)
Number of subjects: 60
Study: 25860402

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 73
Study: 23958264

Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance training 3 times per week for 6 months
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 140
Study: 20646754

Group type: EXPERIMENTAL
Intervention: Educational intervention for parents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 19438539

Group type: EXPERIMENTAL
Intervention: M. vaccae (intradermal injection, three times at 2-week intervals)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo (intradermal injection, three times at 2-week intervals)
Number of subjects: 129
Study: 17416453

Group type: EXPERIMENTAL
Intervention: Monopolar TURP
Number of subjects: 100

Group type: COMPARATOR
Intervention: TURIS (Bipolar TURP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 15145972

Group type: EXPERIMENTAL
Intervention: Omeprazole (OM) 20 mg bid with bismuth biskalcitrate, metronidazole, and tetracycline
Number of subjects: 34

Group type: COMPARATOR
Intervention: Bismuth biskalcitrate, metronidazole, and tetracycline alone
Number of subjects: 34
Study: 11240988

Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Droperidol 20 microg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Metoclopramide 0.2 mg/kg
Number of subjects: 90
Study: 9699568

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study: 8076440

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 1 alpha‐OHD3 (80 ng/kg BW)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of 1 alpha‐OHD3 (80 ng/kg BW)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral administration of 1 alpha‐OHD3 (80 ng/kg BW)
Number of subjects: 8
Study: 2760214

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Estrogen therapy for 3 months
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chronic estrogen therapy
Number of subjects: 72
Study: 20683

Group type: EXPERIMENTAL
Intervention: methantheline bromide
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: flavoxate chloride
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: meladrazine tartrate
Number of subjects: 34

Group type: COMPARATOR
Intervention: cystometric studies
Number of subjects: 34
Study: 30566177

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX) 380 mg every 4 weeks
Number of subjects: 159

Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (BP-NLX) flexible doses (4-24 mg; target dosage 16 mg/d)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: XR-NTX
Number of subjects: 159
Study: 27679664

Group type: EXPERIMENTAL
Intervention: SIMPle intervention (arm A)
Number of subjects: 2560

Group type: EXPERIMENTAL
Intervention: SIMPle intervention (arm B)
Number of subjects: 2560

Group type: COMPARATOR
Intervention: Usual practice control
Number of subjects: 2560
Study: 27137147

Group type: EXPERIMENTAL
Intervention: NEPA in fed condition
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: NEPA in fasted condition
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: NEPA in fasted state for elderly subjects
Number of subjects: 36
Study: 23625291

Group type: EXPERIMENTAL
Intervention: Plecanatide (0.1 to 48.6 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 20971975

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg once daily for 8 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 19268889

Group type: EXPERIMENTAL
Intervention: PermaVision intracorneal lens implantation
Number of subjects: 15
Study: 16769932

Group type: EXPERIMENTAL
Intervention: Active rTMS and placebo medication
Number of subjects: 26

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 26
Study: 12776447

Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler (400 micrograms) once daily
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 10669275

Group type: EXPERIMENTAL
Intervention: Propacetamol 60 mg kg(‐1) i.v.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.4 mg kg(‐1) i.v.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study: 9062568

Group type: EXPERIMENTAL
Intervention: Physical therapy combined with incentive spirometry (IS)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Postoperative pulmonary physical therapy (breathing exercises, secretion removal, mobility)
Number of subjects: 185
Study: 8406337

Group type: EXPERIMENTAL
Intervention: Human growth hormone (HGH) 4 IU/m2/day for 2 years
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Human growth hormone (HGH) 3 IU/m2/day for 2 years
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Human growth hormone (HGH) 2 IU/m2/day for 2 years
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72